07:00 , Jun 9, 2014 |  BioCentury  |  Emerging Company Profile

Anokion: Developing tolerance

Anokion S.A. is using its antigen-specific tolerance platform to develop less immunogenic versions of existing drugs. In the longer term, the company wants to use the technology to develop novel autoimmune therapeutics. For existing protein...
07:00 , Jul 15, 2013 |  BioCentury  |  Emerging Company Profile

Antimmune: Whole antigen vaccines

Antimmune B.V. 's Retoleran therapeutic vaccine technology delivers whole protein antigens to down-regulate pro-inflammatory T cells and induce antigen-specific tolerance and treat autoimmune diseases. The company expects that using the entire disease-specific antigen could result...